Skip to content

SARDAPHARMA

Active Private limited companyfounded 2000active for 26 yearsFinisterraestraat 24, 1000 BrusselsKBO/BCE: BE 0473.270.324

Lifetime

19 annual accounts with figures on one time axis, 24 filings since 2001
peak of €198,401 in 2023
€178,450▼ 10.1%
lowest -€68,900 in 2012
€22,250▲ 174%
peak of €237,664 in 2024
€237,664▲ 10.3%
€717,529▼ 8.6%
peak of 1.5 FTE in 2015
-not published
Board2 names since 2010
1 director
Documentsfilings and deeds
14-11-2025106 days late
2024micro format
Result from €8,134 to €22,250 changes role from manager to director 18-06Cash from €4,951 to €39

Key points

from the 2024 annual accounts

Equity

€237,664 ▲ 10.3%

SARDAPHARMA has made a profit without a break since 2013.

Turnover

≈ €630,000 estimated

The accounts state no turnover.

Debts

€717,529 75% of the balance sheet
Financial debts 78%Suppliers 15%Taxes and wages 2%Other 6%

Of this, €169,308 falls due within a year.

Liquidity

2.26 was 1.59 in 2023

Short-term debts fell from €252,313 to €169,308.

Filings

24 annual accounts 111 days past the deadline
AprilJune31 JulyOctober20102020

2025 accounts not filed: deadline was 31-07-2026.

Position in the sector

€237,664

More equity than 87% of companies in retail trade. The sector median is €39,169, over 25,687 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 4,686 companies had the same profile as SARDAPHARMA has now. Each dot stands for 12 companies, two years later.

96.9%
were still trading
1.9%
stopped another way
1.1%
went bankrupt
  • Small
  • 20 years or older
  • solvency 10 to 30%
  • a profit under 5% of the balance sheet
Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 4,686 companies, not a prediction for SARDAPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 01-01-2010
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0473270324
changes role from manager to director General meeting of 12-06-2024 · Gazette deed
New manager appointed, resigned · Gazette deed
First establishment Finisterraestraat 22-24, Brussels
All 34 events

Comparable companies

same main activity, similar in size and age
Company
SARDAPHARMA Brussels €955,194 €178,450 24.9% -
PHARMACIE PHARMAVIE HARCHIES Bernissart €997,125 €172,555 58.2% 1.6
PHARMACIE KAIRIS Faimes €960,777 €178,032 80.3% 2.2
APOTHEEK ANN JANSSENS Antwerp €983,436 €192,284 85.1% 0
GEASSOCIEERDE APOTHEEK VAN PUYVELDE Antwerp €908,969 €169,017 81.5% 2.7
PHARMACIE VAN TOMME Tournai €983,713 €164,621 41.7% 1
APOTHEEK A. SMEETS Hasselt €927,785 €194,138 42.2% 1.6

These companies have the same main activity as SARDAPHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €909,000 and €997,000, founded between 1999 and 2001.

Official details

Source: KBO
Status
Active since 14-11-2000Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.096.826.8281000 Brussels, since 22-11-2000
Financial year end
31 December
Peppol
Reachable since 13-10-2025
Company details

Annual accounts 2024

€955,194▼ 4.5%
Filing
Filed on 14-11-2025
Financials

Insights on SARDAPHARMA

SARDAPHARMA files the micro format. That format states no turnover. The gross margin rose from €14,062 in 2006 to €178,450 in 2024.

The balance sheet grew most in 2014 through fixed assets, financed with long-term debt.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about SARDAPHARMA

What is the company number of SARDAPHARMA?
The company number of SARDAPHARMA is 0473.270.324. The VAT number is the same number with BE in front: BE 0473.270.324.
Where is SARDAPHARMA based?
The registered office is at Finisterraestraat 24, 1000 Brussels.Company details
What does SARDAPHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of SARDAPHARMA?
SARDAPHARMA is a private limited company (BV).
When was SARDAPHARMA founded?
SARDAPHARMA was founded on 14-11-2000.
Is SARDAPHARMA still active?
Yes, SARDAPHARMA is an active enterprise in the KBO register.
How many employees does SARDAPHARMA have?
SARDAPHARMA had an average of 0.9 full-time equivalents in financial year 2023, according to the filed annual accounts.Financials
What is the turnover of SARDAPHARMA?
The turnover in financial year 2024 is about €630,000. This figure is estimated from the gross margin of €178,450 and 37 comparable companies (NACE 477). It probably lies between €470,000 and €1.1m. In financial year 2020 turnover was €935,656.
Is SARDAPHARMA profitable?
In financial year 2024, SARDAPHARMA made a profit of €22,250.
Where can I find the annual accounts of SARDAPHARMA?
SARDAPHARMA filed 24 annual accounts with the National Bank of Belgium, the latest for financial year 2024.
When are the next annual accounts of SARDAPHARMA due?
SARDAPHARMA had to file the annual accounts for financial year 2025 by 31-07-2026. On 19-11-2026 they are not filed yet, 111 days past the deadline.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.